 SAN DIEGO--BUSINESS WIRE--- GOSS--Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. The Gossamer team enters 2021 excited and focused on clinical trial execution, said Faheem Hasnain, Co-Founder, Chairman an 